AbbVie quarterly revenue rises 10.3% to $17.40 billion
AbbVie's revenue growth is holding steady. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Oct 30, 2026.
Snapshot
AbbVie's revenue growth is holding steady: revenue rose 10.3% to $17.40 billion in the quarter ended September 30, 2026, from $15.78 billion a year earlier, after 10.2% year over year growth the quarter before.
- Independent Research
Market Data
| Company | 1D % | Price |
|---|---|---|
| ($ABBV) | ▲ +1.41% | 294.89 |
as of 16:00 ET · Realtime derived data
What We Know
Revenue for the quarter ended September 30, 2026 was $17.40 billion, versus $15.78 billion in the same quarter a year earlier, up 10.3%. That is its highest quarterly revenue of the last eight quarters.
Quarterly revenue by fiscal quarter end, oldest first: Dec 2024: $15.10 billion; Mar 2025: $13.34 billion; Jun 2025: $15.42 billion; Sep 2025: $15.78 billion; Dec 2025: $16.62 billion; Mar 2026: $15.00 billion; Jun 2026: $16.99 billion; Sep 2026: $17.40 billion.
Octans View
Year over year revenue change by quarter, computed from the filed figures: Dec 2025 up 10.0%; Mar 2026 up 12.4%; Jun 2026 up 10.2%; Sep 2026 up 10.3%. On those figures, AbbVie's revenue growth is holding steady. That read compares the latest two year over year growth rates and nothing else.
Bear Case · Room for Disagreement
This brief covers reported revenue and diluted earnings per share only. It does not cover guidance, margins, segment results, cash flow or the earnings call, and it makes no forecast. Revenue is the total on the release line we matched; a company's own adjusted measures can differ.
Method and source. Octans Research matched the revenue line in the earnings release (Exhibit 99.1) to the year ago quarter the company reported in its own XBRL financial data; the two must agree before anything is published. The quarterly history comes from the same XBRL data. The text is generated from those verified figures by a fixed template; no model wrote it.
Chart
Sources
- [1]SEC EDGAR — AbbVie earnings release for the quarter ended September 30, 2026 (Exhibit 99.1), filed Oct 30, 2026
- [2]SEC EDGAR — AbbVie XBRL financial data (company facts)
These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.
$17.40B
More on $ABBV
4 reports
China's Pipeline Goes Global: The Licensing Wave Rewriting Big Pharma's Deal Math
Chinese biotechs signed licensing deals worth more than 60 billion dollars in the first quarter of 2026 alone. The wave is repricing how multinational pharma sources its pipeline, and the deal structures are telling a more nuanced story than the headline numbers.
Pharmaceutical sector weakness points to systemic rotation over pipeline failures
A synchronized 5 day decline across major drugmakers suggests macro factors are overriding individual clinical narratives.
Newell Brands quarterly revenue rises 3.7% to $1.87 billion
Newell Brands' revenue growth is holding steady. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Oct 30, 2026.
Capri quarterly revenue falls 5.5% to $809.0 million
Capri's revenue decline is deepening. Results for the quarter ended September 26, 2026, from the earnings release filed with the SEC on Oct 30, 2026.